Symbols / VIVS Stock $1.46 -1.35% VivoSim Labs, Inc.

Healthcare • Biotechnology • United States • NCM
VIVS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 4.23M
Enterprise Value 331.62K
Income -1.23M
Sales 142.00K
FCF (ttm) -7.90M
Book/sh 1.70
Cash/sh 1.64
Employees 14
Insider 10d —
IPO Feb 14, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.83
Forward P/E —
PEG —
P/S 29.76
P/B 0.86
P/C —
EV/EBITDA -0.03
EV/Sales 2.33
Quick Ratio 1.75
Current Ratio 2.44
Debt/Eq 18.28
LT Debt/Eq —
EPS (ttm) 1.76
EPS next Y —
EPS Growth —
Revenue Growth 8.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-02-19
Earnings (prior) 2025-02-19
ROA -132.52%
ROE -51.07%
ROIC —
Gross Margin 0.00%
Oper. Margin -105.77%
Profit Margin 0.00%
Shs Outstand 2.89M
Shs Float 2.33M
Insider Own 13.08%
Instit Own 8.07%
Short Float 0.98%
Short Ratio 0.27
Short Interest 27.97K
52W High 5.30
vs 52W High -72.45%
52W Low 1.25
vs 52W Low 16.80%
Beta 1.44
Impl. Vol. —
Rel Volume 0.01
Avg Volume 1.64M
Volume 15.04K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.48
Price $1.46
Change -1.35%
About

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.46
Latest analyst target
3. DCF / Fair value
$-49.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.46
Low
—
High
—
Mean
—
News
RSS: Latest VIVS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-27 STERN ADAM K. Director — 15,000 $0.00 $0
2026-01-27 MURPHY KEITH E Officer and Director — 15,000 $0.00 $0
2026-01-27 GOBEL DAVID Director — 15,000 $0.00 $0
2026-01-27 COHEN DOUGLAS JAY Director — 15,000 $0.00 $0
2026-01-27 MILHOUS ALISON TJOSVOLD Director — 15,000 $0.00 $0
2024-08-07 STERN ADAM K. Director — 19,607 $0.00 $0
2024-08-07 MURPHY KEITH E Officer and Director — 19,607 $0.00 $0
2024-08-07 GOBEL DAVID Director — 19,607 $0.00 $0
2024-08-07 COHEN DOUGLAS JAY Director — 19,607 $0.00 $0
2024-08-07 MILHOUS ALISON TJOSVOLD Director — 19,607 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
0.14
+32.11%
0.11
-70.54%
0.37
-75.33%
1.50
Operating Revenue
0.14
+32.11%
0.11
-70.54%
0.37
-75.33%
1.50
Cost Of Revenue
0.01
0.00
—
—
Reconciled Cost Of Revenue
0.01
0.00
—
—
Gross Profit
0.14
+27.52%
0.11
—
—
Operating Expense
12.76
-16.06%
15.20
-16.05%
18.10
+39.46%
12.98
Research And Development
5.03
-8.60%
5.50
-38.12%
8.88
+167.62%
3.32
Selling General And Administration
7.69
-20.25%
9.64
+6.12%
9.09
-5.64%
9.63
General And Administrative Expense
7.69
-20.25%
9.64
+6.12%
9.09
-5.64%
9.63
Salaries And Wages
0.45
-67.45%
1.37
-28.05%
1.90
+3.65%
1.84
Other Gand A
7.25
-12.44%
8.27
+15.17%
7.18
-7.83%
7.79
Total Expenses
12.76
-16.03%
15.20
-16.05%
18.10
+39.46%
12.98
Operating Income
-12.62
+16.37%
-15.09
+14.92%
-17.73
-54.46%
-11.48
Total Operating Income As Reported
-12.62
+16.37%
-15.09
+14.92%
-17.73
-54.46%
-11.48
EBITDA
-2.21
+84.64%
-14.39
+17.48%
-17.44
-53.81%
-11.34
Normalized EBITDA
-12.21
+15.21%
-14.40
+17.51%
-17.46
-53.99%
-11.34
Reconciled Depreciation
0.27
-5.00%
0.28
-4.44%
0.29
+106.34%
0.14
EBIT
-2.48
+83.12%
-14.67
+17.27%
-17.73
-54.46%
-11.48
Total Unusual Items
10.00
+83233.33%
0.01
-40.00%
0.02
0.00
Total Unusual Items Excluding Goodwill
10.00
+83233.33%
0.01
-40.00%
0.02
0.00
Special Income Charges
10.00
0.00
+100.00%
-0.01
0.00
Net Income
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Pretax Income
-2.49
+83.05%
-14.67
+15.00%
-17.26
-50.77%
-11.45
Net Non Operating Interest Income Expense
0.13
-67.90%
0.41
-10.79%
0.45
+5575.00%
0.01
Interest Expense Non Operating
0.01
0.00
—
—
Net Interest Income
0.13
-67.90%
0.41
-10.79%
0.45
+5575.00%
0.01
Interest Expense
0.01
0.00
—
—
Interest Income Non Operating
0.14
-65.43%
0.41
-10.79%
0.45
+5575.00%
0.01
Interest Income
0.14
-65.43%
0.41
-10.79%
0.45
+5575.00%
0.01
Other Income Expense
10.00
+83233.33%
0.01
-40.00%
0.02
-20.00%
0.03
Other Non Operating Income Expenses
—
—
—
0.03
Gain On Sale Of Security
—
0.01
-58.62%
0.03
—
Tax Provision
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
2.10
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Net Income From Continuing Operation Net Minority Interest
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Net Income From Continuing And Discontinued Operation
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Net Income Continuous Operations
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Normalized Income
-10.39
+29.25%
-14.68
+15.02%
-17.28
-50.93%
-11.45
Net Income Common Stockholders
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Diluted EPS
-1.70
+91.17%
-19.25
+18.98%
-23.76
-50.00%
-15.84
Basic EPS
-1.70
+91.17%
-19.25
+18.98%
-23.76
-50.00%
-15.84
Basic Average Shares
1.46
+92.06%
0.76
+4.96%
0.73
+0.11%
0.73
Diluted Average Shares
1.46
+92.06%
0.76
+4.96%
0.73
+0.11%
0.73
Diluted NI Availto Com Stockholders
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Depreciation Amortization Depletion Income Statement
0.04
-26.42%
0.05
-58.59%
0.13
+357.14%
0.03
Depreciation And Amortization In Income Statement
0.04
-26.42%
0.05
-58.59%
0.13
+357.14%
0.03
Gain On Sale Of PPE
10.00
0.00
+100.00%
-0.01
0.00
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
14.65
+130.74%
6.35
-68.74%
20.31
-38.99%
33.30
Current Assets
12.13
+208.21%
3.94
-76.91%
17.05
-42.27%
29.53
Cash Cash Equivalents And Short Term Investments
11.31
+289.93%
2.90
-81.88%
16.01
-44.18%
28.68
Cash And Cash Equivalents
11.31
+289.93%
2.90
-81.04%
15.30
-46.64%
28.68
Other Short Term Investments
—
0.00
-100.00%
0.71
0.00
Receivables
0.03
-9.09%
0.03
-78.29%
0.15
0.00
Accounts Receivable
0.03
-9.09%
0.03
-78.29%
0.15
0.00
Inventory
0.00
-100.00%
0.30
0.00
—
Finished Goods
0.00
-100.00%
0.30
0.00
—
Prepaid Assets
0.78
+10.84%
0.70
-14.51%
0.82
-4.43%
0.86
Other Current Assets
0.01
+200.00%
0.00
-94.20%
0.07
-91.96%
0.86
Total Non Current Assets
2.52
+4.39%
2.41
-26.09%
3.27
-13.23%
3.76
Net PPE
1.29
-34.65%
1.97
-24.51%
2.61
-7.39%
2.81
Gross PPE
2.81
-12.99%
3.23
-16.92%
3.88
-0.08%
3.89
Accumulated Depreciation
-1.52
-20.91%
-1.26
+1.41%
-1.28
-19.14%
-1.07
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.87
-33.26%
1.30
-23.81%
1.71
-20.81%
2.15
Machinery Furniture Equipment
0.31
+0.00%
0.31
-48.59%
0.60
+7.30%
0.56
Other Properties
1.63
+0.80%
1.62
+2.67%
1.57
+34.50%
1.17
Non Current Prepaid Assets
—
—
—
0.81
Other Non Current Assets
1.23
+177.08%
0.45
-32.37%
0.66
-30.59%
0.95
Total Liabilities Net Minority Interest
4.16
+51.31%
2.75
-44.86%
4.98
+61.45%
3.09
Current Liabilities
3.74
+100.91%
1.86
-49.33%
3.67
+165.44%
1.38
Payables And Accrued Expenses
2.22
+171.15%
0.82
-68.17%
2.57
+446.81%
0.47
Payables
1.64
+162.20%
0.63
+89.43%
0.33
-20.24%
0.41
Accounts Payable
1.64
+162.20%
0.63
+89.43%
0.33
-20.24%
0.41
Current Accrued Expenses
0.57
+200.52%
0.19
-91.47%
2.24
+3970.91%
0.06
Pensionand Other Post Retirement Benefit Plans Current
0.65
+21.64%
0.54
-11.99%
0.61
+40.32%
0.43
Current Debt And Capital Lease Obligation
0.52
+2.96%
0.51
+2.85%
0.49
+2.71%
0.48
Current Capital Lease Obligation
0.52
+2.96%
0.51
+2.85%
0.49
+2.71%
0.48
Other Current Liabilities
0.35
—
—
—
Total Non Current Liabilities Net Minority Interest
0.42
-52.59%
0.89
-32.37%
1.31
-22.95%
1.70
Long Term Debt And Capital Lease Obligation
0.42
-52.59%
0.89
-32.37%
1.31
-22.95%
1.70
Long Term Capital Lease Obligation
0.42
-52.59%
0.89
-32.37%
1.31
-22.95%
1.70
Stockholders Equity
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Common Stock Equity
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Capital Stock
0.00
+100.00%
0.00
-88.89%
0.01
+0.00%
0.01
Common Stock
0.00
+100.00%
0.00
-88.89%
0.01
+0.00%
0.01
Share Issued
1.90
+126.01%
0.84
+15.61%
0.73
+0.07%
0.73
Ordinary Shares Number
1.90
+126.01%
0.84
+15.61%
0.73
+0.07%
0.73
Treasury Shares Number
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Additional Paid In Capital
352.65
+2.73%
343.27
+0.87%
340.32
+0.70%
337.94
Retained Earnings
-342.16
-0.73%
-339.67
-4.51%
-325.00
-5.61%
-307.74
Gains Losses Not Affecting Retained Earnings
—
0.00
-100.00%
0.00
0.00
Treasury Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Other Equity Adjustments
—
—
0.00
—
Total Equity Gross Minority Interest
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Total Capitalization
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Working Capital
8.39
+304.34%
2.08
-84.48%
13.38
-52.48%
28.15
Invested Capital
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Total Debt
0.94
-32.42%
1.39
-22.77%
1.80
-17.32%
2.18
Capital Lease Obligations
0.94
-32.42%
1.39
-22.77%
1.80
-17.32%
2.18
Net Tangible Assets
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Tangible Book Value
10.49
+191.36%
3.60
-76.51%
15.33
-49.26%
30.21
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-9.46
+35.43%
-14.65
-18.09%
-12.41
-46.79%
-8.45
Cash Flow From Continuing Operating Activities
-9.46
+35.43%
-14.65
-18.09%
-12.41
-46.79%
-8.45
Net Income From Continuing Operations
-2.49
+83.04%
-14.67
+15.00%
-17.26
-50.76%
-11.45
Depreciation Amortization Depletion
0.27
-5.00%
0.28
-4.44%
0.29
+106.34%
0.14
Depreciation And Amortization
0.27
-5.00%
0.28
-4.44%
0.29
+106.34%
0.14
Other Non Cash Items
0.43
+6.40%
0.41
—
—
Stock Based Compensation
0.53
-64.72%
1.51
-36.56%
2.38
+5.36%
2.26
Asset Impairment Charge
0.80
0.00
—
—
Operating Gains Losses
-10.00
-83233.33%
-0.01
+40.00%
-0.02
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.01
0.00
Change In Working Capital
1.04
+151.29%
-2.02
-187.68%
2.31
+286.26%
0.60
Change In Receivables
0.00
-97.48%
0.12
+178.29%
-0.15
0.00
Changes In Account Receivables
0.00
-97.48%
0.12
+178.29%
-0.15
0.00
Change In Inventory
-0.50
-68.69%
-0.30
0.00
—
Change In Prepaid Assets
0.25
-35.46%
0.39
+121.47%
0.18
-53.91%
0.38
Change In Payables And Accrued Expense
1.73
+195.01%
-1.82
-182.54%
2.21
+1108.20%
0.18
Change In Accrued Expense
0.72
+133.80%
-2.12
-189.91%
2.36
+4714.29%
0.05
Change In Payable
1.02
+243.58%
0.30
+300.00%
-0.15
-210.45%
0.13
Change In Account Payable
1.02
+243.58%
0.30
+300.00%
-0.15
-210.45%
0.13
Change In Other Working Capital
—
-0.01
-107.14%
0.07
+133.33%
0.03
Change In Other Current Liabilities
-0.45
-9.98%
-0.41
—
—
Investing Cash Flow
9.03
+1006.00%
0.82
+184.47%
-0.97
-136.19%
-0.41
Cash Flow From Continuing Investing Activities
9.03
+1006.00%
0.82
+184.47%
-0.97
-136.19%
-0.41
Net PPE Purchase And Sale
8.99
+21497.62%
-0.04
+89.39%
-0.40
+3.18%
-0.41
Purchase Of PPE
-0.01
+69.05%
-0.04
+89.39%
-0.40
+3.18%
-0.41
Sale Of PPE
9.00
0.00
—
0.00
Capital Expenditure
-0.01
+69.05%
-0.04
+89.39%
-0.40
+3.18%
-0.41
Net Investment Purchase And Sale
0.04
-95.57%
0.86
+250.53%
-0.57
0.00
Purchase Of Investment
-2.96
+72.73%
-10.86
+0.86%
-10.95
0.00
Sale Of Investment
3.00
-74.40%
11.72
+12.85%
10.38
0.00
Financing Cash Flow
8.85
+515.66%
1.44
0.00
-100.00%
0.20
Cash Flow From Continuing Financing Activities
8.85
+515.66%
1.44
0.00
-100.00%
0.20
Net Common Stock Issuance
8.85
+515.66%
1.44
0.00
-100.00%
0.25
Common Stock Payments
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
0.00
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
—
—
—
-0.05
Changes In Cash
8.41
+167.83%
-12.40
+7.28%
-13.37
-54.49%
-8.66
Beginning Cash Position
3.04
-80.29%
15.44
-46.41%
28.82
-23.10%
37.48
End Cash Position
11.46
+276.31%
3.04
-80.29%
15.44
-46.41%
28.82
Free Cash Flow
-9.47
+35.53%
-14.70
-14.77%
-12.80
-44.48%
-8.86
Interest Paid Supplemental Data
0.01
0.00
—
—
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Amortization Of Securities
-0.04
+73.24%
-0.14
-35.24%
-0.10
0.00
Common Stock Issuance
8.85
+515.66%
1.44
0.00
-100.00%
0.25
Earnings Losses From Equity Investments
0.00
+100.00%
-0.01
+58.62%
-0.03
0.00
Issuance Of Capital Stock
8.85
+515.66%
1.44
0.00
-100.00%
0.25
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category